Vanguard Global Advisers
MRVI icon

Vanguard Global Advisers’s Maravai LifeSciences MRVI Stock Holding History

Vanguard Global Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Buy
85,644
+33,876
+65% +$146K ﹤0.01% 2071
2026
Q1 		$147K Buy
+51,768
New +$176K ﹤0.01% 2571

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Global Advisers's MRVI Position: Q2 2026 in Review

Vanguard Global Advisers increased its Maravai LifeSciences (MRVI) stake by 65% in Q2 2026, buying an estimated $146K and bringing the position to 85,644 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Vanguard Global Advisers first reported a position in MRVI in Q1 2026 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Vanguard Global Advisers held 85,644 shares of Maravai LifeSciences worth $534K as of Q2 2026.
  • Vanguard Global Advisers bought 33,876 Maravai LifeSciences shares in Q2 2026, an estimated $146K.
  • Maravai LifeSciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2071 holding.
  • Vanguard Global Advisers first reported a position in Maravai LifeSciences in Q1 2026 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.